Program

Welcome and Chair Remarks
​
Colin D. Weekes, MD, PhD
Massachusetts General Hospital

Genitourinary Cancers

Won Kim, MD
University of California, San Francisco
Genitourinary (Prostate) Cancer
 

Abstract 5000: A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial. (Pirkko-Liisa Kellokumpu-Lehtinen)

Abstract 5001: 68Ga-PSMA11 PET/CT localizes recurrent prostate cancer with high accuracy: Preliminary results from a phase 2/3 prospective trial. (Wolfgang Fendler)

Abstract 5003: Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized Phase II trial. (Noel Clarke)

Abstract 5007: KEYNOTE-199: pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). (Johann De Bono)

Jorge Garcia, MD
Taussig Cancer Institute
Genitourinary (Nonprostate) Cancer
 

Abstract LBA3: CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial. (Arnaud Mejean)

Abstract 4500: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427. (David McDermott)

Abstract 4503: First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt). (Arlene Siefker-Radtke)

Abstract 4511: Patient-reported outcomes (PROs) in IMmotion151: atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). (Bernard Escudier)

Panel Question and Answer

Breast Cancer

William J. Gradishar, MD, FASCO
Northwestern University
Breast Cancer—Local/Regional/Adjuvant

Abstract LBA1: TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score. (Joseph Sparano)

Abstract 104: Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). (Sibylle Loibl)

Abstract 500: Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. (Michael Gnant)

Abstract 506: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. (Helena Earl)


Kevin Kalinsky, MD, MS
Columbia University Medical Center
Breast Cancer—Metastatic

Abstract 1000: Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3. (Dennis Slamon)

Abstract 1005: Everolimus (EVE) + Exemestane (EXE) vs EVE Alone or Capecitabine (CAP) for Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2-negative (HER2-) Advanced Breast Cancer (ABC): BOLERO-6, an Open-label Phase 2 Study. (Guy Jerusalem)

Abstract LBA1006: Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. (Jose Baselga)

Abstract 1007: AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. (Peter Schmid)


Panel Question and Answer

Legislative and Regulatory Update: Practice Management and Policy Issues

Ray D. Page, DO, PhD, FACOI
Center for Cancer and Blood Disorders

Blase N. Polite, MD, MPA, FASCO
University of Chicago Medical Center

Continue the conversation by networking with Faculty at the Legislative Update Networking Roundtables with Complimentary Boxed Lunch.

Legislative Update Networking Roundtables
With Complimentary Boxed Lunch

Ray D. Page, DO, PhD, FACOI
Center for Cancer and Blood Disorders

Blase N. Polite, MD, MPA, FASCO
University of Chicago Medical Center

Patient and Survivor Care

Thomas W. LeBlanc, MD, MS, MHS, FAAHPM
Duke University Medical Center
Patient and Survivor Care

Abstract 10000: Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). (Sherry Shen)

Abstract 10001: The effect of acupuncture versus cognitive behavior therapy on insomnia in cancer survivors: A randomized clinical trial. (Jun Mao)

Abstract LBA10003: Improving Communication with Older Patients with Cancer using Geriatric Assessment (GA): A University of Rochester NCI Community Oncology Research Program (NCORP) Cluster Randomized Controlled Trial (CRCT). (Supriya Mohile)

Abstract 10005: Randomized Trial of a Symptom Monitoring Intervention for Hospitalized Patients with Cancer.(Charn-Xin Fuh)

Question and Answer

Hematologic Malignancies—Leukemia​

Leslie R. Ellis, MD
Wake Forest University
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Abstract 103: Impact of Next-Generation Sequencing (NGS) on Treatment Selection in Acute Myeloid Leukemia (AML). (Rita Assi)

Abstract 7000: Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study. (Daniel Pollyea)

Abstract 7004: Moxetumomab Pasudotox in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia: Results of a Pivotal International Study. (Robert Kreitman)

Abstract 7010: Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML). (Courtney Dinardo)

Hematologic Malignancies—Lymphoma and Plasma Cell Dyscrasia​

Peter Martin, MD
Weill Cornell Medicine
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Abstract 7500: RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma.(Nathan Fowler)

Abstract 7501: Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM). (Roger Owen)

Abstract 7502: Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL). (William Wierda)

Abstract 7505: Updated Safety & Long Term Clinical Outcomes in TRANSCEND NHL 001, Pivotal Trial of Lisocabtagene Maraleucel (JCAR017) in R/R Aggressive NHL. (Jeremy Abramson)


Noopur S. Raje, MD
Massachusetts General Hospital Cancer Center
Hematologic Malignancies—Plasma Cell Dyscrasia

Abstract 8000: Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W. (Maria-Victoria Mateos)

Abstract 8003: Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's Macroglobulinemia. (Meletios Dimopoulos)

Abstract 8004: Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. (Luciano Costa)

Abstract 8008: FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response. (Aviva Krauss)

Panel Question and Answer